Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moya, B. Articles by Oliver, A. Search for Related Content PubMed PubMed Citation Articles by Moya, B. Articles by Oliver, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3694-3700, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00172-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Benefit of Having Multiple ampD Genes for Acquiring β-Lactam Resistance without Losing Fitness and Virulence in Pseudomonas aeruginosa

Bartolomé Moya,^1,2 Carlos Juan,^1,2 Sebastián Albertí,^2,3 José L. Pérez,^1,2 and Antonio Oliver^1,2*

Servicio de Microbiología and Unidad de Investigación, Hospital Son Dureta,¹ Instituto Universitario de Investigación en Ciencias de la Salud (IUNICS),² Area de Microbiología, Universidad de las Islas Baleares, Palma de Mallorca, Spain³

Received 6 February 2008/ Returned for modification 23 April 2008/ Accepted 16 July 2008

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The inactivation of ampD in Pseudomonas aeruginosa leads to a partially derepressed phenotype, characterized by a moderately high level basal ampC expression that is still further inducible, due to the presence of two additional ampD genes in this species (ampDh2 and ampDh3). The sequential inactivation of the three ampD genes was shown to lead to a stepwise upregulation of ampC expression, reaching full derepression in the triple mutant. To gain insight into the biological role of P. aeruginosa AmpD multiplicity, we determined the effects of the inactivation of the ampD genes on fitness and virulence. We show that, in contrast to what was previously documented for Salmonella spp., the inactivation of ampD in P. aeruginosa does not affect fitness or virulence in a mouse model of systemic infection. This lack of effect was demonstrated to be dependent on the presence of the additional ampD genes (ampDh2 and ampDh3), since the double and the triple ampD mutants completely lost their biological competitiveness and virulence; full ampC derepression and disruption of the AmpD peptidoglycan recycling system itself are both found to cause a major biological cost. Furthermore, among the ampD genes, ampDh3 is found to be the most relevant for virulence in P. aeruginosa. Therefore, as a consequence of the presence of additional ampD genes, partial ampC derepression mediated by ampD inactivation confers a biologically efficient resistance mechanism on P. aeruginosa.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Pseudomonas aeruginosa, as well as many other nonfermenting gram-negative bacilli and most members of the Enterobacteriaceae, produces a chromosomally encoded group I, class C cephalosporinase designated AmpC (2). Although AmpC is produced at very low basal levels in wild-type strains, its expression is highly inducible in the presence of certain β-lactams (β-lactamase inducers) such as cefoxitin or imipenem (23). In fact, the antipseudomonal penicillins (such as ticarcillin or piperacillin) and cephalosporins (such as ceftazidime or cefepime) are very weak AmpC inducers, despite the fact that they are hydrolyzed by this enzyme (23). For this reason, during treatment with these weak inducers, mutants showing constitutively high level AmpC production (AmpC-derepressed mutants) are frequently selected, leading to the failure of antimicrobial therapy (8, 14, 15, 22).

Several genes are involved in the regulation of ampC expression, a process that is intimately linked to peptidoglycan recycling (28). ampG encodes a transmembrane permease for 1,6-anhydromurapeptides, which are thought to be the signal molecules involved in AmpC induction, through interaction with the LysR-type transcriptional regulator AmpR (5, 12, 13, 18, 20). During regular bacterial growth, muropeptides are processed by the N-acetyl-anhydromuramyl-L-alanine amidase AmpD, which therefore plays two major roles: (i) it is required for the recycling of peptidoglycan catabolism products, and (ii) it prevents ampC induction (11, 21, 28). On the other hand, during growth in the presence of strong β-lactamase inducers such as cefoxitin, muropeptides are generated and accumulate in the cytoplasm (due to the saturation of AmpD), leading to the AmpR-mediated induction of ampC expression (5, 12, 13, 20, 28). It is also well known that the mutational inactivation of AmpD leads to the accumulation of muropeptides and high-level ampC expression, even in the absence of β-lactamase inducers, producing the classical constitutively derepressed phenotype of AmpC production (21, 28). In fact, AmpD inactivation is the most frequently reported mechanism leading to AmpC hyperproduction and β-lactam resistance both in Enterobacteriaceae and in P. aeruginosa clinical isolates (1, 15, 19, 31).

The interplay between resistance mechanisms and bacterial fitness and virulence is a subject of growing interest. The latter are indeed key parameters for predicting the clinical relevance of the resistance mechanisms (effect on virulence), as well as their epidemiological transcendence, dependent on their capacity for persistence in bacterial populations once the selective pressure exerted by the antibiotics disappears (effect on fitness) (25, 26). Previous work with Salmonella spp., which lack the ampC gene but contain ampD, has revealed two interesting findings in this field: (i) the inactivation of ampD in Salmonella spp. is associated with a significant biological cost and decreased virulence, mediated by the accumulation of muropeptides (7), and (ii) high-level expression of ampC from a foreign plasmid also leads to significant decreases in virulence and in vivo fitness (27).

Interestingly, in contrast to the classical fully derepressed phenotypes observed in Enterobacteriaceae, the inactivation of AmpD in P. aeruginosa has been shown to lead to a partially derepressed phenotype, characterized by a moderately high level basal ampC expression that is still further inducible in the presence of inducers (19). Recent studies have shown that the partial derepression of the P. aeruginosa ampD mutant is due to the presence of two additional ampD genes, designated ampDh2 and ampDh3, in this species (16). Furthermore, the sequential inactivation of the three ampD genes has been shown to lead to a stepwise upregulation of ampC expression, reaching full derepression with very high level basal ampC expression (more than 1,000-fold compared to wild-type expression) in the triple mutant (16). Certainly, this is an interesting and complex system that needs to be studied further, since it is the first instance in which the expression of a chromosomally encoded resistance mechanism can be sequentially amplified through multiple steps of derepression. In this work, we explored the biological role of P. aeruginosa AmpD multiplicity in providing a mechanism for the sequential amplification of an antibiotic resistance gene and in avoiding the biological cost of the first-step resistant mutant (single ampD mutant).

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Bacterial strains, plasmids, and antibiotics. Laboratory strains and plasmids used or constructed in this work are listed in Table 1. We used the P. aeruginosa reference strain PAO1 and the previously constructed single ampD gene knockout mutants (PAD [ampD], PADh2 [ampDh2], and PADh3 [ampDh3]), double ampD mutants (PADDh2 [ampD ampDh2] and PADDh3 [ampD ampDh3]), and triple ampD mutant (PADDh2Dh3 [ampD ampDh2 ampDh3]) (16). These mutants had been constructed by following the procedure described by Quénée et al. (29) for gene deletion and antibiotic resistance marker recycling in P. aeruginosa using the cre-lox system. By this procedure, two isogenic pairs of strains were obtained for each of the knockout mutants: one with and one without the (gentamicin) resistance marker (16). The antibiotics used (gentamicin, ampicillin, carbenillicin, and tetracycline) were purchased from Sigma-Aldrich.

View this table: [in this window] [in a new window]

TABLE 1. Strains and plasmids used or constructed

Construction of ampC knockout mutants. The procedure for gene deletion and antibiotic resistance marker recycling in P. aeruginosa using the cre-lox system, described above, was used for the construction of the ampC knockout mutants of PAO1 (PAC) and of the triple ampD mutant (PADDh2Dh3C). Briefly, upstream and downstream PCR products (Table 2) of ampC were digested with either BamHI or EcoRI and HindIII and then cloned by three-way ligation into pEX100Tlink deleted for the HindIII site and opened by EcoRI and BamHI to produce plasmid pEXAC, which was transformed into Escherichia coli strain XL1-Blue. Transformants were selected on LB agar (LBA) plates with 30 µg/ml ampicillin. The lox-flanked gentamicin resistance cassette (aac1) obtained by HindIII restriction of plasmid pUCGmlox was cloned into the single site for this enzyme formed by ligation between the two flanking fragments, producing plasmid pEXACGm, which was transformed into E. coli XL1-Blue. Transformants were selected on LBA plates with 30 µg/ml ampicillin and 5 µg/ml gentamicin. These plasmids were then transformed into the E. coli helper strain S17-1. Plasmid pEXACGm was transferred from E. coli S17-1 to PAO1 or PADDh2Dh3 to produce the PACGm or PADDh2Dh3CGm mutant, respectively, after selection for double recombinants using LBA plates with 5% sucrose and 30 µg/ml gentamicin. Double recombinants were checked first by screening for susceptibility to carbenillicin (200 µg/ml) and afterwards by PCR amplification using primers AmpC-F-ERI and AmpC-R-BHI (Table 2). For the recycling of the gentamicin resistance cassettes (to yield the PAC and PADDh2Dh3C mutants), plasmid pCM157 was electroporated into the different mutants as previously described (30). Transformants were selected on LBA plates with 250 µg/ml tetracycline. One transformant for each mutant was grown overnight in LB broth with 250 µg/ml tetracycline in order to allow the expression of the cre recombinase. Plasmid pCM157 was then cured from the strains by three successive passages in LB broth. Selected colonies were then screened for susceptibility to tetracycline (250 µg/ml) and gentamicin (30 µg/ml) and were checked by PCR amplification and DNA sequencing.

View this table: [in this window] [in a new window]

TABLE 2. Primers used for the construction of the ampC knockout mutants

In vitro competition experiments. In vitro competition experiments between each of the ampD mutants (harboring the gentamicin resistance marker) described above and PAO1 were performed. Additionally, competition experiments were performed between strains PADDh2Dh3CGm and PADDh2Dh3 (triple ampD mutants with and without ampC inactivated) and between strains PACGm and PAO1 as controls. Exponentially growing cells of the corresponding mutant and wild-type strains in LB broth were mixed in a 1:1 ratio and diluted in 0.9% saline solution. Approximately 10³ cells from each of the mixtures were inoculated into eight 10-ml LB broth flasks and grown at 37°C and 180 rpm for 16 to 18 h, corresponding to approximately 20 generations. Serial 10-fold dilutions were plated in duplicate onto LBA alone and LBA with 15 µg/ml of gentamicin (LBA-Gm) in order to determine the total CFU and the CFU of the mutant, respectively, after overnight incubation at 37°C. Alternatively, when the difference in the number of colonies between the LBA and LBA-Gm plates was low (less than twofold), 100 randomly selected colonies from the LBA plates were replicated in LBA-Gm plates; mutant and wild-type colonies were recognized by the presence or absence of growth in these plates after overnight incubation. The competition index (CI) was defined as the mutant/wild-type ratio. CI values were calculated for each of the eight independent competitions, and the median values were recorded. Statistical analysis of the distribution of the CI values was performed using the Mann-Whitney U test. P values of <0.05 were considered to be statistically significant. During the standardization of the procedure, competition experiments between strains PADGm (PAO1 ampD mutant harboring the Gm resistance cassette) and PAD (PAO1 ampD mutant not harboring the Gm resistance cassette) were performed; the CI values obtained (median CI, 0.95) ruled out any significant effect of the gentamicin resistance cassette on bacterial fitness. To assess the growth rates under noncompetitive conditions, the doubling times of exponentially growing cells in LB broth at 37°C and 180 rpm were determined by plating serial 10-fold dilutions on LBA at 1-h intervals. Three independent experiments were performed for each of the mutants, and the results were compared with those for PAO1 using Student's t test.

Virulence and fitness in the mouse model of systemic infection. To assess the effect on virulence, approximately 5 x 10⁶ exponentially growing cells of PAO1, PAD, PADh2, PADh3, PADDh2, PADDh3, PADDh2Dh3, or PADDh2Dh3C were inoculated intraperitoneally into groups of 16 ICR(CD1) mice (Harlan Interfauna Ibérica, Barcelona, Spain) weighing 20 to 25 g, and mortality was monitored daily for 7 days. In vivo fitness was assessed by competition experiments in the mouse model of systemic infection. For this purpose, 1:1 mixtures of each of the mutant-wild-type pairs containing a total of approximately 5 x 10⁶ exponentially growing cells were inoculated intraperitoneally into eight 20- to 25-g ICR(CD1) mice. When indicated (see Results), competition experiments were also performed using a starting mutant/wild-type ratio of 10:1 or 10:10. Mice were sacrificed 24 h after inoculation, and their spleens were aseptically extracted and homogenized in 2 ml of 0.9% saline solution using the Ultra-Turrax T-25 disperser (IKA, Staufen, Germany). The number of CFU of each strain and the CI values were determined as described for in vitro competition experiments.

Sequencing of the ampDh2 and ampDh3 genes in AmpC-hyperproducing clinical P. aeruginosa isolates. A collection of 10 previously characterized pairs of isogenic clinical strains was further studied (15). Each pair of strains consisted of an isolate showing wild-type AmpC production and a subsequent isogenic isolate showing AmpC hyperproduction, obtained after treatment with β-lactams (15). Each pair of clinical strains was recovered from a different patient, and each pair belonged to a different clone (15). Six of the 10 AmpC-hyperproducing isolates had previously been shown to contain ampD-inactivating mutations (15). In the present work, we explored whether these isolates may additionally contain inactivating mutations in ampDh2 and/or ampDh3. For this purpose, these genes were amplified by PCR using primer pairs ADh2-FBHI-ADh2-RBHI and ADh3-FBHI-ADh3-RBHI, described previously (16), and were fully sequenced for the 10 pairs of isolates. Sequencing reactions were performed with the BigDye Terminator kit (Perkin-Elmer Applied Biosystems, Foster City, CA), and sequences were analyzed on an ABI Prism 3100 DNA sequencer (Perkin-Elmer Applied Biosystems). The resulting sequences were then compared (http://blast.ncbi.nlm.nih.gov/Blast.cgi) with those previously reported for the wild-type PAO1 strain (16).

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
In vitro competition experiments. Figure 1 shows the CI values obtained for each of the in vitro competition experiments, and Table 3 summarizes the data on ampC expression and ceftazidime susceptibility, obtained as part of a previous work (16), as well as presenting the doubling time of each of the mutants studied. None of the single or double ampD mutants showed a significant modification of the growth rate; doubling times ranged from 28.3 to 37.6 min (30.0 min for PAO1) (Table 3). On the other hand, the triple ampD mutant (PADDh2Dh3), in which AmpC was fully derepressed, showed a clearly reduced growth rate, with a doubling time of 78.2 min (P = 0.01 for comparison to PAO1) (Table 3). Consistent with the growth rates, the results for the PADGm-PAO1 competition (median CI, 0.78; P = 0.8) showed that the inactivation of ampD in PAO1 was not associated with a significant fitness cost in vitro (Fig. 1). The ampD ampDh2 double mutant was not associated with a significant cost, either (median CI for the PADDh2Gm-PAO1 competition, 0.83), and the ampD ampDh3 double mutant showed only a modest (though statistically significant [P = 0.0003]) reduction in fitness (median CI for the PADDh3Gm-PAO1 competition, 0.61) (Fig. 1). On the other hand, the simultaneous inactivation of the three ampD genes resulted in a marked decrease in fitness, as shown by the median CI of 0.25 for the PADDh2Dh3Gm-PAO1 competition (P < 0.0001). Nevertheless, the documented doubling time for the triple ampD mutant (double that for wild-type PAO1) should predict a much lower CI (approximately 0.001) in the competition experiments. The higher-than-expected CI might be explained by the fact that the differences in the growth rate between the triple ampD mutant and PAO1 were not that sharp in late-log phase (data not shown).

View larger version (14K): [in this window] [in a new window]

FIG. 1. Results of in vitro competition experiments. In vitro competitions were performed in LB broth flasks in which bacteria were grown at 37°C and 180 rpm for 16 to 18 h, corresponding to approximately 20 generations, as described in Materials and Methods. The CI values obtained for each of the eight independent experiments are plotted. The median CI values are shown in parentheses.

View this table: [in this window] [in a new window]

TABLE 3. ampC expression, ceftazidime susceptibilities, and doubling times for the mutants characterized

To explore whether ampC derepression was responsible for the reduced fitness of the triple ampD mutant, the corresponding ampC knockout mutants were constructed. As shown in Fig. 1, ampC derepression itself was found to be the main factor responsible for the in vitro cost documented, since inactivation of ampC restored the fitness of the triple ampD mutant to wild-type levels (median CI for the PADDh2Dh3CGm-PAO1 competition, 0.80; P = 0.9). Similarly, the triple ampD mutant with ampC inactivated clearly outcompeted the triple ampD mutant (median CI for the PADDh2Dh3CGm-PADDh2Dh3 competition, 4.28; P < 0.0001) (Fig. 1). Furthermore, the inactivation of ampC in the triple ampD mutant restored its growth rate to wild-type levels (doubling time, 37.6 min) (Table 3). Control competition experiments between the PAO1 ampC mutant (PAC) and PAO1 ruled out any significant effect of ampC inactivation on fitness in the wild-type strain (median CI, 0.95) (Fig. 1). Similarly, the growth rate of PAC was not modified from that of PAO1 (Table 3). Overall, the results of the in vitro experiments show that P. aeruginosa can tolerate moderate overexpression (up to 2 log units) of AmpC without a significant effect on growth but that, in contrast, when the level of AmpC expression reaches a certain threshold (around 3 log units), fitness is significantly reduced.

Fitness and virulence in the mouse model of systemic infection. Results for the in vivo competition experiments in the mouse model of systemic infection are presented in Table 4. As shown, all the single ampD mutants retained full in vivo fitness relative to that of the wild-type strain, since none of them was outcompeted by PAO1 (median CI values, 0.94 to 1.02). On the other hand, the ampD ampDh2 double mutant was associated with a significant biological cost (median CI, 0.23; P < 0.001), and the ampD ampDh3 double mutant lost its biological competitiveness completely (median CI, <0.01). Accordingly, the ampD ampDh2 ampDh3 triple mutant was completely outcompeted by PAO1, even when the competition experiments were performed with an initial 10:1 mutant/wild-type ratio (Table 4). Furthermore, in contrast to the results of in vitro competitions, ampC inactivation did not restore the in vivo fitness of the triple mutant at all (median CI for the PADDh2Dh3CGm-PAO1 competition, <0.01), showing that AmpC derepression is not the main driver of the marked biological cost determined by the sequential inactivation of the ampD genes. Nevertheless, ampC derepression itself caused a significant reduction of in vivo fitness, since the triple mutant with ampC inactivated clearly outcompeted the triple mutant (median CI for the PADDh2Dh3CGm-PADDh2Dh3 competition, 12.5).

View this table: [in this window] [in a new window]

TABLE 4. Results of in vivo competition experiments in the mouse model of systemic infection

To assess the effect on virulence of the inactivation of the ampD genes, the mortality rates for groups of 16 mice inoculated with each of the strains studied were monitored daily for 7 days. As shown in Fig. 2, the inactivation of ampD or ampDh2 did not modify the mouse survival curve at all. On the other hand, remarkably, the inactivation of ampDh3 dramatically reduced mortality to 0% after 7 days, suggesting that this gene plays a major role in virulence. Accordingly, no mortality was observed for the ampD ampDh3 double mutant (Fig. 2), the triple mutant, or the triple mutant with ampC inactivated (data not shown). Finally, the ampD ampDh2 double mutant produced significantly (P < 0.001) lower mortality than either the ampD or the ampDh2 single mutant (Fig. 2).

View larger version (9K): [in this window] [in a new window]

FIG. 2. Percentages of survival over time for groups of 16 mice inoculated intraperitoneally with 5 x 106 CFU of PAO1, PAD, PADh2, PADh3, PADDh2, or PADDh3. After 7 days, the percentage of survival for mice inoculated with strain PADDh2Dh3 or PADDh2Dh3C was 100% (data not included in the graph).

Sequencing of the ampDh2 and ampDh3 genes in AmpC-hyperproducing P. aeruginosa clinical isolates. The natural occurrence of P. aeruginosa double or triple ampD mutants was investigated in a collection of 10 previously characterized pairs of isogenic clinical strains (15). Each pair of strains consisted of an isolate showing wild-type AmpC production and a subsequent isogenic isolate showing AmpC hyperproduction, obtained after treatment with β-lactams (15). Each pair of clinical strains was recovered from a different patient, and each belonged to a different clone (15). Six of the 10 AmpC-hyperproducing isolates had previously been found to contain ampD-inactivating mutations, whereas the mechanisms leading to AmpC hyperproduction were unknown for the other 4 strains (15) (Table 5). The results of the sequencing of the ampDh2 and ampDh3 genes are shown in Table 5. Although some of the strains showed differences of one amino acid from the sequence of PAO1 (Table 5), these substitutions were always present in the wild-type isogenic isolates, suggesting that they are natural polymorphisms rather than inactivating mutations and therefore that double and triple ampD mutants are not frequent in the clinical setting.

View this table: [in this window] [in a new window]

TABLE 5. Results of sequencing of the ampD genes from a collection of 10 ceftazidime-resistant, AmpC-hyperproducing clinical strains

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
The development of resistance by Pseudomonas aeruginosa during antimicrobial therapy, mediated by the selection of mutations in chromosomal genes, is a frequent problem with major clinical consequences (3, 6, 24). Particularly noteworthy among the mutation-mediated resistance mechanisms are those leading to the hyperproduction of the chromosomal cephalosporinase AmpC, which confers resistance to all the antipseudomonal penicillins and cephalosporins (23). Indeed, failure of treatment with β-lactams due to the selection of AmpC-hyperproducing mutants is a frequent outcome of P. aeruginosa infections (8, 15, 22). Furthermore, AmpC hyperproduction is one of the most prevalent resistance mechanisms documented among clinical P. aeruginosa strains, even among those isolated from patients with severe bloodstream infections (10), showing that the pathogenic capacity is not at all impaired. Along the same lines, AmpC hyperproduction is a frequent contributor to multidrug resistance in P. aeruginosa (9) and, combined with other mutational resistance mechanisms, is responsible for the origination of panresistant epidemic clones (4).

In contrast to the classical phenotype of full AmpC derepression generally reported for Enterobacteriaceae, P. aeruginosa clinical isolates most frequently show partially derepressed phenotypes (23). Indeed, the inactivation of AmpD in this species leads to a moderately high level basal ampC expression that is still further inducible in the presence of inducers, due to the production of two additional N-acetyl-anhydromuramyl-L-alanine amidases, AmpDh2 and AmpDh3 (16, 19). Homology searches using the available databases with the complete genome sequences of E. coli and other members of the Enterobacteriaceae revealed the presence of one, and only one, ampD homologue in addition to the regular ampD gene (16). This additional N-acetyl-anhydromuramyl-L-alanine amidase has recently been fully characterized in E. coli, where it has been designated AmiD (32). AmiD was shown to contain the signal sequence of outer membrane lipoproteins, and indeed its location in the outer membrane was demonstrated, in contrast to the cytoplasmic location of AmpD (32). P. aeruginosa AmpDh2 has the same signal sequence of outer membrane lipoproteins, suggesting that this amidase is the AmiD homologue. Therefore, AmpDh3 appears to be the extra amidase of P. aeruginosa. Indeed, AmpDh3 was previously shown to contribute much more than AmpDh2 to ampC repression in the ampD mutant background, thus playing a more relevant role in the characteristic partially derepressed phenotype of P. aeruginosa (16).

In this work we show that AmpD multiplicity in P. aeruginosa plays a major role in coupling the acquisition of antibiotic resistance with the maintenance of biological competitiveness and virulence. While full AmpC derepression is shown to impose a marked fitness cost both in vitro and in vivo, partial derepression, mediated by ampD inactivation in the presence of ampDh2 and particularly ampDh3, does not modify biological competitiveness. Furthermore, independently of ampC expression, the inactivation of two or all three ampD genes imposes a marked biological cost in the mouse model, whereas in vivo fitness is not affected in any of the single ampD mutants. Nevertheless, remarkably, in contrast to the inactivation of ampD or ampDh2, ampDh3 inactivation dramatically reduced the mortality of mice, suggesting that this gene plays a major role in virulence. The reason for the differential effect on virulence of ampDh3 inactivation, compared to ampD or ampDh2 inactivation, still remains to be elucidated. One of the possibilities that should be further explored is a potential role in cell wall degradation for the establishment of gaps in peptidoglycan, which are required for the assembly of type III and IV secretion systems (17).

Previous studies have shown that AmpD is required for the recycling of peptidoglycan catabolism products and that its inactivation leads to the accumulation of muropeptides (28). Furthermore, a recent work showed that the accumulation of muropeptides, determined by ampD inactivation, causes a marked reduction of in vivo fitness and virulence in Salmonella enterica (7). Indeed, this marked difference in the biological consequences of ampD inactivation between Salmonella enterica and P. aeruginosa is expected to be dependent on the presence of AmpDh3 in the latter species; the single ampD mutant of Salmonella enterica should be equivalent to the P. aeruginosa ampD ampDh3 double mutant, which is completely impaired in fitness and virulence.

While full ampC derepression in P. aeruginosa, mediated by the sequential inactivation of the three ampD genes, confers high-level resistance to antipseudomonal β-lactams and partial derepression confers only moderate resistance, our results predict that the former phenotype should be very uncommon in the clinical setting, due to its high biological cost. Consistent with this hypothesis, none of the 10 natural AmpC-hyperproducing mutants characterized in this work seemed to contain inactivating mutations in ampDh2 or ampDh3. Nevertheless, previous work shows that there are yet unidentified pathways, independent of the ampD genes, leading to high-level ampC expression, whose effects on fitness and virulence remain to be explored (15, 19).

In summary, we show that P. aeruginosa AmpD multiplicity plays a major role in coupling the acquisition of antibiotic resistance with the maintenance of biological competitiveness and virulence. Due to the presence of ampDh2 and ampDh3, partial ampC derepression mediated by ampD inactivation confers a biologically efficient resistance mechanism on P. aeruginosa.

 
We are grateful to two anonymous reviewers for comments and suggestions.

This work was supported by the Ministerio de Educación y Ciencia of Spain (SAF2006-08154), the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, through the Spanish Network for Research in Infectious Diseases (REIPI C03/14 and RD06/0008), and the Govern de les Illes Balears (PROGECIB-9A).

 
* Corresponding author. Mailing address: Servicio de Microbiología, Hospital Son Dureta, C. Andrea Doria No. 55, 07014 Palma de Mallorca, Spain. Phone and fax: 34 971 175 185. E-mail: aoliver{at}hsd.es

Published ahead of print on 21 July 2008.

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1
1. Bagge, N., O. Ciofu, M. Hentzer, J. I. A. Campbell, M. Givskov, and N. Hoiby. 2002. Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob. Agents Chemother. 46:3406-3411.[Abstract/Free Full Text]
2
2. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.[Medline]
3
3. Carmeli, Y., N. Troillet, G. M. Eliopoulos, and M. S. Samore. 1999. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risk associated with different antipseudomonal agents. Antimicrob. Agents Chemother. 43:1379-1382.[Abstract/Free Full Text]
4
4. Deplano, A., O. Denis, L. Poirel, D. Hocquet, C. Nonhoff, B. Byl, P. Nordmann, J. L. Vincent, and M. J. Struelens. 2005. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol. 43:1198-1204.[Abstract/Free Full Text]
5
5. Dietz, H., D. Pfeifle, and B. Wiedemann. 1997. The signal molecule for β-lactamase induction in Enterobacter cloacae is the anhydromuramyl-pentapeptide. Antimicrob. Agents Chemother. 41:2113-2120.[Abstract]
6
6. Fish, D. N., S. C. Piscitelli, and L. H. Danziger. 1995. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15:279-291.[Medline]
7
7. Folkesson, F., S. Eriksson, M. Andersson, J. T. Park, and S. Normark. 2005. Components of the peptidoglycan-recycling pathway modulate invasion and intracellular survival of Salmonella enterica serovar Typhimurium. Cell. Microbiol. 7:147-155.[CrossRef][Medline]
8
8. Giwercman, B., P. A. Lambert, V. T. Rosdahl, G. H. Shand, and N. Hoiby. 1990. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J. Antimicrob. Chemother. 26:247-259.[Abstract/Free Full Text]
9
9. Henrichfreise, B., I. Wiegand, W. Pfister, and B. Wiedemann. 2007. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob. Agents Chemother. 51:4062-4070.[Abstract/Free Full Text]
10
10. Hocquet, D., P. Berthelot, M. Roussel-Delvallez, R. Favre, K. Jeannot, O. Bajolet, N. Marty, F. Grattard, P. Mariani-Kurkdjan, E. Bingen, M. O. Housson, G. Couetdic, and P. Plesiat. 2007. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother. 51:3531-3536.[Abstract/Free Full Text]
11
11. Höltje, J. V., U. Kopp, A. Ursinus, and B. Wiedemann. 1994. The negative regulator of β-lactamase induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase. FEMS Microbiol. Lett. 122:159-164.[CrossRef][Medline]
12
12. Honoré, N., M. H. Nicolas, and S. T. Cole. 1986. Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli. EMBO J. 5:3709-3714.[Medline]
13
13. Jacobs, C., L. Huang, E. Bartowsky, S. Normark, and J. T. Park. 1994. Bacterial cell wall recycling provides cytosolic muropeptides as effectors for β-lactamase induction. EMBO J. 13:4684-4694.[Medline]
14
14. Juan, C., O. Gutiérrez, A. Oliver, J. I. Ayestarán, N. Borrell, and J. L. Pérez. 2005. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin. Microbiol. Infect. 11:887-892.[CrossRef][Medline]
15
15. Juan, C., M. D. Maciá, O. Gutiérrez, C. Vidal, J. L. Pérez, and A. Oliver. 2005. Molecular mechanisms of β-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49:4733-4738.[Abstract/Free Full Text]
16
16. Juan, C., B. Moyá, J. L. Pérez, and A. Oliver. 2006. Stepwise upregulation of the Pseudomonas aeruginosa chromosomal cephalosporinase conferring high-level β-lactam resistance involves three AmpD homologues. Antimicrob. Agents Chemother. 50:1780-1787.[Abstract/Free Full Text]
17
17. Koraimann, G. 2003. Lytic transglycosylases in macromolecular transport systems of Gram-negative bacteria. Cell. Mol. Life Sci. 60:2371-2388.[CrossRef][Medline]
18
18. Korfmann, G., and C. C. Sanders. 1989. ampG is essential for high-level expression of AmpC beta-lactamase in Enterobacter cloacae. Antimicrob. Agents Chemother. 33:1946-1951.[Abstract/Free Full Text]
19
19. Langaee, T. Y., L. Cagnon, and A. Huletsky. 2000. Inactivation of the ampD gene in Pseudomonas aeruginosa leads to moderate-basal-level and hyperinducible AmpC β-lactamase expression. Antimicrob. Agents Chemother. 44:583-589.[Abstract/Free Full Text]
20
20. Lindberg, F., L. Westman, and S. Normark. 1985. Regulatory components in Citrobacter freundii ampC β-lactamase induction. Proc. Natl. Acad. Sci. USA 82:4620-4624.[Abstract/Free Full Text]
21
21. Lindberg, F., S. Lindquist, and S. Normark. 1987. Inactivation of the ampD gene causes semiconstitutive overproduction of the inducible Citrobacter freundii β-lactamase. J. Bacteriol. 169:1923-1928.[Abstract/Free Full Text]
22
22. Livermore, D. M. 1987. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur. J. Clin. Microbiol. 6:439-445.[CrossRef][Medline]
23
23. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.[Abstract]
24
24. Livermore, D. M. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.[CrossRef][Medline]
25
25. Martínez, J. L., and F. Baquero. 2002. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin. Microbiol. Rev. 15:647-679.[Abstract/Free Full Text]
26
26. Martínez, J. L., F. Baquero, and D. I. Andersson. 2007. Predicting antibiotic resistance. Nat. Rev. Microbiol. 5:958-965.[CrossRef][Medline]
27
27. Morosini, M. I., J. A. Ayala, F. Baquero, J. L. Martínez, and J. Blázquez. 2000. Biological cost of AmpC production for Salmonella enterica serotype Typhimurium. Antimicrob. Agents Chemother. 44:3137-3143.[Abstract/Free Full Text]
28
28. Normark, S. 1995. β-Lactamase induction in Gram-negative bacteria is intimately linked to peptidoglycan recycling. Microb. Drug Resist. 1:111-114.[Medline]
29
29. Quénée, L., D. Lamotte, and B. Polack. 2005. Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa. BioTechniques 38:63-67.[Medline]
30
30. Smith, A. W., and B. H. Iglewski. 1989. Transformation of Pseudomonas aeruginosa by electroporation. Nucleic Acids Res. 17:10509.[Free Full Text]
31
31. Stapleton, P., K. Shannon, and I. Phillips. 1995. DNA sequence differences of ampD mutants of Citrobacter freundii. Antimicrob. Agents Chemother. 39:2494-2498.[Abstract]
32
32. Uehara, T., and J. T. Park. 2007. An anhydro-N-acetylmuramyl-L-alanine amidase with broad specificity tethered to the outer membrane of Escherichia coli. J. Bacteriol. 189:5634-5641.[Abstract/Free Full Text]

---

Antimicrobial Agents and Chemotherapy, October 2008, p. 3694-3700, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00172-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Lister, P. D., Wolter, D. J., Hanson, N. D. (2009). Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms. Clin. Microbiol. Rev. 22: 582-610 [Abstract] [Full Text]  
• Asgarali, A., Stubbs, K. A., Oliver, A., Vocadlo, D. J., Mark, B. L. (2009). Inactivation of the Glycoside Hydrolase NagZ Attenuates Antipseudomonal {beta}-Lactam Resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53: 2274-2282 [Abstract] [Full Text]  
• Jacoby, G. A. (2009). AmpC {beta}-Lactamases. Clin. Microbiol. Rev. 22: 161-182 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Moya, B. Articles by Oliver, A. Search for Related Content PubMed PubMed Citation Articles by Moya, B. Articles by Oliver, A.